Canaccord analyst Whitney Ijem lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $11 from $34 and keeps a Buy rating on the shares. The firm noted last week’s announcement of a clinical hold on lead program RP-A501 for Danon Disease following AEs (adverse event), a protocol adjustment, new AEs and ultimately a patient death. This is a clear setback from a timing and sentiment perspective.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts
- Rocket Pharmaceuticals downgraded at Evercore following patient death in study
- Rocket Pharmaceuticals downgraded to In Line from Outperform at Evercore ISI
- Rocket Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan
- Rocket Pharmaceuticals price target lowered to $19 from $51 at Scotiabank